Jazz Pharmaceuticals plc Stock
Jazz Pharmaceuticals plc Stock
A loss of -2.540% shows a downward development for Jazz Pharmaceuticals plc.
The stock is an absolute favorite of our community with 35 Buy predictions and no Sell predictions.
As a result the target price of 176 € shows a slightly positive potential of 6.31% compared to the current price of 165.55 € for Jazz Pharmaceuticals plc.
Pros and Cons of Jazz Pharmaceuticals plc in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Jazz Pharmaceuticals plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc | -2.540% | 2.191% | 3.404% | 81.803% | 14.647% | 25.941% | 20.751% |
| Opko Health Inc. | 3.160% | 4.466% | 1.449% | -15.401% | -10.108% | -22.737% | -71.944% |
| Amicus Therapeutics Inc. | 0.290% | 0.123% | 0.123% | 98.618% | 1.792% | 20.941% | 58.636% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 0.000% | -2.674% | -9.901% | -5.208% | -7.143% | -35.000% | -9.901% |
Comments
Jazz Pharmaceuticals (JAZZ) had its price target raised by Piper Sandler from $219.00 to $232.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (JAZZ) had its "overweight" rating reaffirmed by Barclays PLC.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (JAZZ) is now covered by Barclays PLC. They set an "overweight" rating and a $224.00 price target on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat